![](/img/cover-not-exists.png)
Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?
Berkelmans, Gijs F. N., Greving, Jacoba P., van der Graaf, Yolanda, Visseren, Frank L. J., Dorresteijn, Jannick A. N.Volume:
4
Journal:
Diagnostic and Prognostic Research
DOI:
10.1186/s41512-020-00072-5
Date:
December, 2020
File:
PDF, 2.29 MB
2020